A Comprehensive Clinical and Pharmacological Review of Citalopram (DB00215)

1.0 Introduction and Drug Identification

1.1 Overview and Classification

Citalopram is a widely prescribed antidepressant medication belonging to the class of selective serotonin reuptake inhibitors (SSRIs).[1] As a small molecule drug, its primary therapeutic application is in the management of major depressive disorder and other mood-related conditions.[1] A defining feature of citalopram is its pharmacological profile; among all SSRIs, it is recognized as one of the most selective inhibitors of serotonin reuptake, a characteristic that fundamentally shapes its clinical efficacy and tolerability.[1]

The global significance of citalopram in mental healthcare is underscored by its inclusion in the World Health Organization (WHO) Model List of Essential Medicines for the treatment of depressive disorders.[2] Its extensive clinical use is further highlighted by prescription statistics; in 2022, it was the 40th most commonly prescribed medication in the United States, accounting for over 15 million prescriptions.[3]

1.2 Historical Development and Regulatory Milestones

The journey of citalopram from laboratory synthesis to a cornerstone of depression treatment illustrates key trends in pharmaceutical development and public health. The molecule was first synthesized in 1972 by the Danish pharmaceutical company Lundbeck, which subsequently patented the compound.[4] The path to market was protracted, involving a rigorous 15-year period of development and clinical trials to establish its efficacy and safety profile.[4] This lengthy timeline is not unusual for neuropsychiatric agents, where demonstrating a clear therapeutic benefit against a complex and variable disease background presents significant scientific and regulatory challenges.

Citalopram was first launched commercially in Denmark in 1989 under the brand name Cipramil.[4] Its approval in the United States by the Food and Drug Administration (FDA) followed nearly a decade later, on July 17, 1998, for the treatment of depression; it was marketed by Forest Laboratories as Celexa.[2] An oral solution formulation received approval on December 22, 1999.[6]

Under patent protection, citalopram became Lundbeck's flagship product. However, the patent expired in 2003, a pivotal event that transformed its market dynamics.[4] This opened the door for numerous pharmaceutical companies, including Aurobindo, Mylan, and Dr. Reddy's Labs, to introduce generic versions starting in 2004.[6] The resulting competition led to a significant reduction in cost, dramatically increasing the drug's accessibility. This economic shift positioned citalopram as a preferred therapeutic choice for national health services, such as the UK's NHS, and cemented its role in global mental health treatment.[4] The economic lifecycle of citalopram thus demonstrates the dynamic interplay between the need to incentivize pharmaceutical innovation through patent-protected profits and the public health imperative to provide widespread access to essential medicines via affordable generics.

Citalopram is marketed globally under a multitude of brand names, with the most prominent being Celexa in the United States and Canada, and Cipramil across Europe and Australia.[3]

1.3 Chemical and Physical Properties

Citalopram is chemically classified as a racemic bicyclic phthalane derivative.[1] Its chemical structure is unrelated to that of other SSRIs, tricyclic antidepressants (TCAs), or other classes of antidepressant agents.[7] The systematic chemical name for the compound is (±)-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile.[7] It is typically administered as its hydrobromide salt, which appears as a fine white to off-white crystalline powder.[10] The salt form is sparingly soluble in water but soluble in ethanol.[9]

The distinct physicochemical properties of citalopram are fundamental to its identity and pharmacological behavior. These properties, summarized in Table 1, are essential for researchers in fields such as medicinal chemistry and pharmacology for experimental design, formulation development, and understanding its pharmacokinetic profile. For instance, its lipophilicity, indicated by the LogP value, is a key determinant of its ability to cross the blood-brain barrier and exert its effects within the central nervous system.

Table 1: Chemical and Physical Properties of Citalopram

Property	Value	Source(s)
Identifier
DrugBank ID	DB00215	1
CAS Number	59729-33-8	1
Molecular Details (Base)
Molecular Formula	C20​H21​FN2​O	9
Molecular Weight	324.40 g/mol	9
Molecular Details (HBr Salt)
Molecular Formula	C20​H22​BrFN2​O	7
Molecular Weight	405.35 g/mol	7
Physical Properties
Melting Point	91.0 to 95.0 °C (base)	9
Solubility (Water)	Sparingly soluble	9
pKa	9.38	12
LogP	3.76	11

2.0 Pharmacodynamics: Mechanism of Action

2.1 Primary Mechanism: Selective Serotonin Reuptake Inhibition

The therapeutic effects of citalopram in treating depression are presumed to arise from its potentiation of serotonergic activity within the central nervous system (CNS).[2] It achieves this through a highly specific mechanism: the potent and selective inhibition of the neuronal serotonin transporter (SERT), a protein also known as solute carrier family 6 member 4 (SLC6A4).[1] By binding to and inhibiting SERT, citalopram blocks the reabsorption (reuptake) of the neurotransmitter serotonin (5-hydroxytryptamine, or 5-HT) from the synaptic cleft back into the presynaptic neuron. This action leads to an increased concentration of serotonin in the synapse, enhancing its availability to bind with and stimulate postsynaptic receptors.[13]

Citalopram is distinguished among SSRIs for its high degree of selectivity for SERT. It demonstrates minimal effects on the neuronal reuptake of other key monoamines, such as norepinephrine (NE) and dopamine (DA).[1] This selectivity is quantifiable through its inhibitory constants; the half-maximal inhibitory concentrations (

IC50​) for the uptake of 5-HT, NE, and DA are approximately 1.8 nM, 8800 nM, and 41000 nM, respectively, illustrating a profound preference for the serotonin system.[12]

2.2 Receptor Binding Profile and Clinical Implications

A key aspect of citalopram's pharmacodynamic profile is its lack of significant affinity for a wide array of other neurotransmitter receptors. It has no or very low affinity for 5-HT₁A, 5-HT₂A, dopamine D₁ and D₂, α₁-, α₂-, and β-adrenergic, histamine H₁, gamma-aminobutyric acid (GABA), muscarinic cholinergic, and benzodiazepine receptors.[1]

This "clean" receptor binding profile is a critical differentiator from older classes of antidepressants, particularly the tricyclic antidepressants (TCAs). TCAs often exert significant antagonistic effects at muscarinic, histaminergic, and adrenergic receptors, which are responsible for many of their burdensome side effects. Citalopram's lack of binding at these sites explains its generally improved tolerability, with fewer anticholinergic effects (e.g., dry mouth, blurred vision, constipation), less sedation (from histamine H₁ blockade), and a lower risk of cardiovascular issues like orthostatic hypotension (from α₁-adrenergic blockade) compared to TCAs.[1] It is noted, however, that citalopram possesses a mild antihistamine property, which may contribute to some of its sedating effects in certain individuals.[3]

2.3 Stereochemistry and Enantiomeric Activity

Citalopram is commercially available and administered as a racemic mixture, which means it contains equal proportions (50/50) of two stereoisomers, or enantiomers: (S)-citalopram and (R)-citalopram.[8] The primary therapeutic activity of the drug—the inhibition of serotonin reuptake—is almost exclusively attributed to the (S)-enantiomer.[8] In vitro studies have quantified this difference, showing that S-citalopram is approximately 167 times more potent than R-citalopram at inhibiting SERT.[14]

Further investigation has revealed that the (R)-enantiomer is not merely an inert component of the racemic mixture. Some evidence suggests that R-citalopram may actively counteract the serotonin-enhancing effects of the therapeutically active S-enantiomer.[9] This finding provided a compelling scientific and commercial rationale for the subsequent development of escitalopram (marketed as Lexapro), which is the pure S-enantiomer of citalopram. The hypothesis was that by isolating the active enantiomer, a more potent and efficient drug could be created. This would allow for a lower therapeutic dose (e.g., 10 mg of escitalopram is considered equivalent to 20 mg of citalopram) to achieve a similar or greater clinical effect, potentially with an improved side-effect profile, as the patient would not be exposed to the counterproductive R-enantiomer. This strategic development represents a clear example of how understanding stereochemistry can lead to the refinement of existing therapeutics.

3.0 Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

3.1 Absorption and Bioavailability

Citalopram exhibits linear and dose-proportional pharmacokinetics following oral administration, a characteristic that was established within a dose range of 10 to 60 mg/day, although current clinical guidelines cap the maximum recommended dose at 40 mg/day due to safety concerns.[7] The drug is well-absorbed from the gastrointestinal tract, with a high absolute oral bioavailability of approximately 80% when compared to an intravenous dose.[1]

Following a single oral dose, peak plasma concentrations (Tmax​) are typically reached in about 4 hours.[1] The absorption of citalopram is not affected by the presence of food, which provides flexibility in its administration schedule.[1] With consistent once-daily dosing, steady-state plasma concentrations are achieved within approximately one week.[7]

3.2 Distribution

Citalopram is a lipophilic compound, a property that facilitates its distribution throughout the body.[13] It has a large apparent volume of distribution (

Vd​) of approximately 12 L/kg, indicating extensive penetration into tissues beyond the bloodstream, including efficient passage across the blood-brain barrier to reach its target sites in the CNS.[1] The binding of citalopram and its primary metabolites, demethylcitalopram (DCT) and didemethylcitalopram (DDCT), to human plasma proteins is moderate, at approximately 80%.[1]

3.3 Metabolism

The biotransformation of citalopram occurs predominantly in the liver.[1] The primary metabolic pathway is N-demethylation, which converts citalopram into its main metabolites: demethylcitalopram (DCT) and, subsequently, didemethylcitalopram (DDCT).[1] Other minor metabolites that have been identified include citalopram-N-oxide and a deaminated propionic acid derivative.[7]

The metabolism is mediated by the cytochrome P450 (CYP) enzyme system. The key enzymes responsible for the initial N-demethylation step are CYP2C19 and CYP3A4.[1] The subsequent conversion to DDCT involves CYP2D6.[1] While these metabolites are formed, they are significantly less potent as serotonin reuptake inhibitors than the parent citalopram molecule and are not believed to contribute meaningfully to the drug's overall antidepressant effect.[1] However, the DDCT metabolite has been implicated as the primary agent responsible for the cardiotoxic effect of QT interval prolongation, a key safety concern with citalopram.[14]

3.4 Excretion

Citalopram has a mean terminal elimination half-life (t1/2​) of approximately 35 hours, with a reported range of 24 to 48 hours.[1] This relatively long half-life supports the convenience of a once-daily dosing regimen. The drug is eliminated from the body through both renal and hepatic pathways. Following an oral dose, approximately 12-23% is excreted unchanged in the urine, while about 10% is recovered in the feces.[1] The total systemic clearance of citalopram is approximately 330 mL/min, with renal clearance contributing about 20% to this total.[1]

3.5 Pharmacogenomic Considerations

The pharmacokinetics of citalopram are significantly influenced by genetic factors, particularly polymorphisms in the gene encoding the CYP2C19 enzyme. This variability has profound clinical implications for dosing and safety.

Individuals can be classified based on their CYP2C19 genotype into different metabolizer phenotypes. Those classified as "poor metabolizers" (PMs) possess genetic variants that result in a non-functional or severely deficient CYP2C19 enzyme. In these individuals, the clearance of citalopram is markedly reduced. Studies have shown that in CYP2C19 PMs, the steady-state maximum concentration (Cmax​) and total drug exposure (Area Under the Curve, or AUC) are increased by 68% and 107%, respectively, compared to normal metabolizers.[7] This substantial increase in drug levels directly elevates the risk of dose-dependent adverse effects, most notably QT prolongation. As a result, regulatory agencies and clinical guidelines have established a lower maximum recommended dose of 20 mg per day for patients known to be CYP2C19 poor metabolizers.[2]

This direct causal chain—from genetics to enzyme function, to drug metabolism, to plasma concentration, and finally to clinical risk—is a clear illustration of how pharmacokinetics drives modern clinical practice. The "standard" 40 mg dose of citalopram is effectively an overdose for a significant and identifiable subset of the population. This has compelled a shift away from a "one-size-fits-all" prescribing model toward a stratified approach where a patient's genetics, age, liver function, and co-medications are critical factors for determining a safe dose.

Beyond CYP2C19, other genetic markers have been explored for their potential association with citalopram response and side effects. For example, certain genotypes of the serotonin 5-HT₂A receptor and glutamate receptors (GRIK2, GRIK4) have been linked to a higher likelihood of therapeutic response, while variants in other glutamate receptor genes (GRIK2, GRIA3) may correlate with an increased frequency of suicidal ideation.[1] Furthermore, polymorphisms in the gene for the multidrug resistance protein 1 (ABCB1) may help predict the likelihood of achieving remission from depression with citalopram treatment.[1]

4.0 Clinical Applications and Efficacy

4.1 FDA-Approved Indication: Major Depressive Disorder (MDD)

Citalopram is officially approved by the U.S. Food and Drug Administration (FDA) for the treatment of depression in adults aged 18 years and older.[1] The indication is specifically for patients whose diagnosis corresponds to the criteria for Major Depressive Disorder (MDD) as defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM).[7] Its efficacy for this indication was established in short-term, placebo-controlled clinical trials lasting 4 to 6 weeks.[10] It has also been evaluated in Phase 2 clinical trials as an adjunctive therapy for MDD.[17]

A critical aspect of patient education and management is the characteristic delayed onset of action for SSRIs. While some improvement may be noted earlier, the initial therapeutic effects of citalopram typically become apparent within 1 to 4 weeks of starting treatment. A full clinical response may take considerably longer, often requiring 8 to 12 weeks of continuous therapy.[1] It is important to note that citalopram is

not approved by the FDA for use in pediatric patients, and evidence for its effectiveness in this population is considered uncertain.[3]

4.2 Common Off-Label Applications

Beyond its approved indication, citalopram is widely used off-label to treat a broad spectrum of psychiatric and medical conditions.[1] This extensive off-label use suggests that clinicians have observed its utility across disorders that may share an underlying neurobiology involving serotonin dysregulation.

• Anxiety Disorders: While not FDA-approved for these conditions, citalopram is licensed in the United Kingdom and other European countries for the treatment of panic disorder, with or without agoraphobia.[3] In the U.S., it is commonly used off-label for panic disorder, social anxiety disorder, and generalized anxiety disorder.[1]
• Obsessive-Compulsive Disorder (OCD): Citalopram is frequently prescribed off-label to help manage the intrusive thoughts and compulsive behaviors characteristic of OCD.[1]
• Other Conditions: A variety of other off-label applications have been documented, including the treatment of premenstrual dysphoric disorder (PMDD), vasomotor symptoms of menopause (hot flashes), binge-eating disorder, alcohol use disorder, and neuropathic pain associated with diabetes.[1]

The broad range of these off-label applications, from mood and anxiety disorders to eating disorders and even thermoregulatory issues like hot flashes, acts as a clinical confirmation of the diverse roles of serotonin in the CNS. Serotonin is known to modulate not only mood but also fear circuitry, impulse control, appetite, and temperature regulation.[1] The effectiveness of a SERT inhibitor across these varied conditions suggests they may not be entirely distinct pathological entities but rather different clinical manifestations of a common vulnerability in the serotonergic system. In this way, clinical practice with citalopram has helped reinforce our understanding of neurobiology.

4.3 Comparative Efficacy

In clinical comparisons, citalopram has demonstrated efficacy comparable to that of other antidepressant medications, but often with a superior tolerability profile, meaning fewer side effects.[3] A comprehensive analysis by the UK's National Institute for Health and Clinical Excellence (NICE), which ranked ten common antidepressants on both efficacy and cost-effectiveness, placed citalopram fifth in terms of effectiveness (following mirtazapine, escitalopram, venlafaxine, and sertraline) and fourth in cost-effectiveness.[3]

5.0 Dosage and Administration

5.1 Formulations and Strengths

Citalopram is available for oral administration in several formulations and strengths to accommodate different patient needs and dosing strategies.

• Tablets: The most common formulation, available in strengths of 10 mg, 20 mg, and 40 mg.[2] A 60 mg tablet was previously marketed but has been discontinued due to safety concerns related to cardiac effects.[6]
• Capsules: A 30 mg capsule formulation is also available.[15]
• Oral Solution: A liquid formulation is available at a concentration of 10 mg per 5 mL, which can be useful for patients who have difficulty swallowing tablets or require fine dose titration.[2]

5.2 Dosing Regimens and Administration

Citalopram is administered once daily. It can be taken either in the morning or in the evening, and its absorption is not affected by food.[2] If the medication causes insomnia, taking the dose in the morning is often recommended.[18]

• Major Depressive Disorder (Adults <60 years): The standard initial dose is 20 mg once daily. If clinically warranted, this dose may be increased to the maximum recommended dose of 40 mg once daily. Dose increases should not occur more frequently than once a week.[2] Doses exceeding 40 mg per day are not recommended because they do not provide additional therapeutic benefit for depression but significantly increase the risk of QT interval prolongation.[15]
• Off-Label Dosing Examples:
• Panic Disorder: Treatment is typically initiated at 10 mg or 20 mg per day, with titration up to a maximum dose of 40 mg per day based on patient response and tolerability.[15]
• Obsessive-Compulsive Disorder: An initial dose of 20 mg per day is common, which may be titrated up to 40-60 mg per day. It is critical to note that doses above 40 mg/day exceed the general maximum and require a careful risk-benefit assessment by the prescribing clinician, particularly regarding cardiac safety.[15]

5.3 Dosing Adjustments in Special Populations

Safe prescribing of citalopram is critically dependent on appropriate dose adjustments for specific patient populations who are at higher risk of adverse effects. The risk of toxicity is not uniform, and failure to modify the dose in these groups can lead to serious harm. Table 2 consolidates the recommended dosage adjustments from multiple clinical sources, providing an essential tool for enhancing patient safety by highlighting populations where the standard dose is inappropriate or contraindicated.

Table 2: Citalopram Dosage Adjustments in Special Populations

Population	Maximum Recommended Dose	Rationale for Adjustment	Source(s)
Geriatric Patients (>60 years)	20 mg/day	Reduced drug clearance, increased half-life, and heightened risk of QT prolongation and hyponatremia (as noted in the Beers Criteria).	2
Hepatic Impairment	20 mg/day	Citalopram clearance is reduced by 37% and its half-life is doubled, leading to increased drug exposure and risk of QT prolongation.	2
Poor CYP2C19 Metabolizers	20 mg/day	Genetic deficiency in the primary metabolizing enzyme leads to significantly increased drug exposure (AUC increased by 107%), elevating the risk of QT prolongation.	2
Coadministration with CYP2C19 Inhibitors	20 mg/day	Concomitant use of strong CYP2C19 inhibitors (e.g., cimetidine, omeprazole, fluconazole) mimics the poor metabolizer phenotype, increasing citalopram levels.	15
Severe Renal Impairment (CrCl<20mL/min)	Use with caution	The pharmacokinetics of citalopram have not been adequately studied in this population; effects are unknown.	2

6.0 Safety Profile and Adverse Effects

6.1 FDA Boxed Warning: Suicidality

Citalopram, in line with the entire class of antidepressant medications, carries a Boxed Warning from the FDA. This is the most serious type of warning issued by the agency. The warning highlights an increased risk of suicidal thoughts and behaviors (suicidality) in children, adolescents, and young adults (up to age 24) during short-term clinical trials for MDD and other psychiatric disorders.[2]

Due to this risk, it is imperative that all patients initiating citalopram therapy, regardless of age, be monitored closely. This monitoring should be most intensive during the first 1 to 2 months of treatment and following any changes in dosage. Clinicians, patients, and caregivers must watch for signs of clinical worsening, the emergence of suicidal ideation, or unusual changes in behavior, such as agitation, irritability, or impulsivity.[2]

6.2 Common Adverse Effects

The most frequently reported side effects of citalopram are often extensions of its primary pharmacological action—increased serotonergic activity—both in the CNS and in the periphery, particularly the gastrointestinal tract.[3] These effects are often most pronounced at the beginning of treatment and may diminish over time as the body adapts.

• Gastrointestinal: Nausea is the most common side effect, affecting up to 20% of patients. Other common GI effects include dry mouth (xerostomia), diarrhea, constipation, and vomiting.[2]
• Central Nervous System (CNS): Drowsiness or sleepiness, insomnia (difficulty sleeping), dizziness, headache, and tremor are frequently reported.[2]
• Dermatologic: Increased sweating (diaphoresis) is a common complaint.[2]
• Sexual Dysfunction: Adverse effects on sexual function are common with SSRIs and are often a reason for non-adherence. These include dose-dependent ejaculation disorder in males, as well as decreased libido and difficulty achieving orgasm in both sexes.[2]

6.3 Serious Adverse Events and Risks

While generally well-tolerated, citalopram is associated with several serious risks that require careful consideration and monitoring. The safety profile can be understood as having two distinct components: first, a set of risks common to the SSRI class as a whole (suicidality, serotonin syndrome, discontinuation syndrome), and second, a drug-specific, dose-dependent cardiovascular risk (QT prolongation) that is more pronounced with citalopram than with many of its peers. This specific risk profile fundamentally shapes its place in therapy and necessitates a more nuanced risk assessment than for other SSRIs.

6.3.1 Cardiovascular Effects: QT Prolongation

A primary safety concern with citalopram is its dose-dependent potential to prolong the QT interval of the electrocardiogram (ECG).[13] Compared to other commonly prescribed SSRIs, citalopram has a significantly higher odds ratio of causing clinically relevant QTc prolongation.[14] The proposed mechanism involves its metabolite, didesmethylcitalopram (DDCT), which blocks the human ether-à-go-go-related gene (hERG) potassium channel (

IKr​). This channel is critical for the repolarization phase of the cardiac action potential. By blocking it, the metabolite slows cardiac repolarization, which manifests as a longer QT interval on an ECG.[14] A QTc interval exceeding 500 milliseconds is associated with a heightened risk of developing Torsades de Pointes, a potentially fatal polymorphic ventricular arrhythmia.[14] This risk is the primary reason why doses above 40 mg per day (or 20 mg/day in at-risk populations) are strictly contraindicated.[15]

6.3.2 Serotonin Syndrome

This is a potentially life-threatening condition resulting from excessive serotonergic activity in the CNS.[13] The risk is highest when citalopram is taken in overdose or combined with other serotonergic agents. Symptoms can range from mild to severe and include a triad of autonomic hyperactivity (fever, sweating, rapid heart rate), neuromuscular abnormalities (muscle rigidity, twitching, tremor, loss of coordination), and altered mental status (agitation, confusion, hallucinations).[22]

6.3.3 Hyponatremia and SIADH

Citalopram can cause or exacerbate hyponatremia (low blood sodium levels), often as a consequence of the Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH).[2] This risk is particularly pronounced in older adults, especially those concurrently using diuretics. This specific risk is a key reason for citalopram's inclusion in the Beers Criteria as a potentially inappropriate medication for the geriatric population.[2] Close monitoring of serum sodium levels is recommended when initiating or adjusting the dose in older patients.[2]

6.3.4 Discontinuation Syndrome

Abrupt cessation of citalopram therapy can trigger a withdrawal-like state known as antidepressant discontinuation syndrome.[3] Symptoms include dizziness, nausea, fatigue, headache, anxiety, agitation, sleep disturbances, and sensory disturbances often described as "electric shock" sensations or "brain zaps".[18] To prevent this syndrome, a gradual dose reduction (taper) over several weeks to months is strongly recommended whenever discontinuing the medication.[18]

7.0 Drug-Drug Interactions

The interaction profile of citalopram is extensive and clinically significant, primarily revolving around three mechanisms: potentiation of serotonergic effects, additive QT prolongation, and inhibition of its own metabolism. Safe prescribing requires a holistic patient view, as the convergence of these risks can be common, especially in older adults with polypharmacy. For example, an older patient with depression might also be treated for hypertension with a diuretic (increasing hyponatremia and QT risk), for acid reflux with omeprazole (a CYP2C19 inhibitor that increases citalopram levels), and for arthritis with an NSAID (increasing bleeding risk). The addition of citalopram to this regimen creates a cascade of interacting risks that must be managed proactively.

7.1 Contraindicated Combinations

Certain drug combinations with citalopram are absolutely contraindicated due to the high risk of severe, life-threatening adverse events.

• Monoamine Oxidase Inhibitors (MAOIs): Concurrent use of citalopram with MAOIs (e.g., isocarboxazid, phenelzine, selegiline) is contraindicated due to the high risk of serotonin syndrome. A mandatory "washout" period of at least 14 days is required when switching from an MAOI to citalopram, or vice versa.[15] This contraindication also extends to other drugs that possess MAOI properties, such as the antibiotic linezolid and the dye methylene blue.[15]
• Other Contraindicated Drugs: Several other drugs are contraindicated, primarily because of an unacceptable additive risk of QT prolongation and Torsades de Pointes. These include the antipsychotic pimozide, the antiarrhythmic dronedarone, the antifungal fluconazole, and GnRH agonists like goserelin and leuprolide.[15]

7.2 Clinically Significant Interactions

A large number of drugs can interact with citalopram, requiring close monitoring or avoidance. Table 3 categorizes the most important interactions by their mechanism of action, providing a conceptual framework for risk assessment.

Table 3: Major and Moderate Drug Interactions with Citalopram

Mechanism of Interaction	Interacting Drug Class / Specific Drug	Potential Outcome & Management	Source(s)
Increased Serotonin Syndrome Risk	Other SSRIs (sertraline, fluoxetine), SNRIs (venlafaxine, duloxetine), TCAs (amitriptyline), Triptans (sumatriptan), Opioids (tramadol, fentanyl), St. John's Wort	Additive serotonergic effects. Combination should be avoided or used with extreme caution and close monitoring for symptoms of serotonin syndrome.	14
Additive QT Prolongation	Antiarrhythmics (amiodarone, sotalol), Antipsychotics (quetiapine, ziprasidone), Certain Antibiotics (azithromycin, ciprofloxacin), Methadone	Increased risk of life-threatening cardiac arrhythmias (Torsades de Pointes). Avoid combination if possible. If necessary, requires frequent ECG monitoring.	14
Increased Citalopram Levels (CYP2C19 Inhibition)	Proton Pump Inhibitors (omeprazole, esomeprazole), H₂ Blockers (cimetidine), Certain Antifungals (fluconazole)	Inhibition of citalopram's primary metabolic pathway, leading to increased plasma levels and higher risk of toxicity (especially QT prolongation). Citalopram dose should not exceed 20 mg/day.	15
Increased Bleeding Risk	NSAIDs (ibuprofen, naproxen), Anticoagulants (warfarin, apixaban), Antiplatelet agents (clopidogrel, aspirin)	SSRIs can impair platelet aggregation. Combination increases risk of bleeding, particularly gastrointestinal bleeding. Use with caution and monitor for signs of bleeding.	13
Additive CNS Depression	Alcohol, Benzodiazepines (alprazolam, lorazepam), Opioids, Sedative-hypnotics	Increased sedation, drowsiness, and impairment of cognitive and motor skills. Patients should be advised to avoid or limit alcohol and use caution when taking other CNS depressants.	23

8.0 Conclusion and Clinical Summary

Citalopram is an established and effective antidepressant whose therapeutic utility is derived from its highly selective inhibition of serotonin reuptake. This pharmacological precision affords it a generally favorable tolerability profile compared to older, less selective antidepressant agents, making it a valuable tool in the management of major depressive disorder.

However, the clinical application of citalopram requires a careful balance of its efficacy against a distinct and significant safety profile. Its primary liability is a dose-dependent risk of QT interval prolongation, a drug-specific concern that is more pronounced than with many other SSRIs and has necessitated strict regulatory dosing caps. Furthermore, its metabolic reliance on the CYP2C19 enzyme renders it susceptible to both pharmacogenomic variability and a wide range of drug-drug interactions. This necessitates a personalized approach to prescribing, moving beyond standard doses to consider individual patient factors.

In contemporary clinical practice, citalopram remains a viable and important first-line option for many patients with MDD, especially when cost and accessibility are key considerations due to its availability as an inexpensive generic. However, its use demands caution. It may not be the ideal choice for patients with pre-existing cardiac conditions, a personal or family history of long QT syndrome, uncorrected electrolyte imbalances (hypokalemia, hypomagnesemia), or for those on complex polypharmacy regimens, particularly the elderly. In such cases, alternative SSRIs with a more favorable cardiovascular safety profile, such as sertraline or its own purified enantiomer, escitalopram, may be preferable.

Ultimately, the cornerstone of safe and effective citalopram therapy lies in meticulous patient selection, individualized dosing based on a comprehensive assessment of risk factors—including age, hepatic function, genetic predispositions, and co-medications—and vigilant monitoring for both therapeutic benefits and the emergence of adverse events.

Works cited

1. Citalopram: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed July 30, 2025, https://go.drugbank.com/drugs/DB00215
2. Citalopram - StatPearls - NCBI Bookshelf, accessed July 30, 2025, https://www.ncbi.nlm.nih.gov/books/NBK482222/
3. Citalopram - Wikipedia, accessed July 30, 2025, https://en.wikipedia.org/wiki/Citalopram
4. Citalopram - Molecule of the Month - November 2009 - HTML-only ..., accessed July 30, 2025, https://www.chm.bris.ac.uk/motm/citalopram/citalopramh.htm
5. Drug Approval Package:Celexa Tablets (Citalopram Hydrobromide) NDA# 20-822, accessed July 30, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020822a.cfm
6. Generic Celexa Availability - Drugs.com, accessed July 30, 2025, https://www.drugs.com/availability/generic-celexa.html
7. Celexa Label - accessdata.fda.gov, accessed July 30, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020822s047lbl.pdf
8. Celexa® (citalopram) Tablets Rx Only Suicidality and Antidepressant Drugs Antidepressants increased the risk - accessdata.fda.gov, accessed July 30, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020822s052lbl.pdf
9. Citalopram 59729-33-8 | TCI AMERICA - TCI Chemicals, accessed July 30, 2025, https://www.tcichemicals.com/MX/en/p/C3149
10. Citalopram HBr - accessdata.fda.gov, accessed July 30, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20822lbl.pdf
11. Citalopram | C20H21FN2O | CID 2771 - PubChem, accessed July 30, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/2771
12. Citalopram | 59729-33-8 - ChemicalBook, accessed July 30, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5244937.htm
13. Citalopram Hydrobromide Mechanism, Uses, and Safety Profile | Request PDF, accessed July 30, 2025, https://www.researchgate.net/publication/384661371_Citalopram_Hydrobromide_Mechanism_Uses_and_Safety_Profile
14. Citalopram weekly summary - TAPNA, accessed July 30, 2025, https://tapna.org.au/wp-content/uploads/2021/08/Citalopram-weekly-summary-1628040895.2873.pdf
15. Celexa (citalopram) dosing, indications, interactions, adverse effects ..., accessed July 30, 2025, https://reference.medscape.com/drug/celexa-citalopram-342958
16. Citalopram: Side Effects, Uses, Dosage, Interactions, Warnings - Rx List, accessed July 30, 2025, https://www.rxlist.com/citalopram/generic-drug.htm
17. Citalopram Completed Phase 2 Trials for Depression / Major Depressive Disorder (MDD) Treatment | DrugBank Online, accessed July 30, 2025, https://go.drugbank.com/drugs/DB00215/clinical_trials?conditions=DBCOND0018735%2CDBCOND0030181&phase=2&purpose=treatment&status=completed
18. How and when to take citalopram - NHS, accessed July 30, 2025, https://www.nhs.uk/medicines/citalopram/how-and-when-to-take-citalopram/
19. Celexa Dosage Guide: Recommended Citalopram Doses - GoodRx, accessed July 30, 2025, https://www.goodrx.com/celexa/dosage
20. Citalopram Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed July 30, 2025, https://www.drugs.com/dosage/citalopram.html
21. 10 Possible Side Effects of Citalopram, a Treatment for Depression - GoodRx, accessed July 30, 2025, https://www.goodrx.com/citalopram/side-effects-of-taking-celexa
22. Citalopram oral tablet side effects: What to do about them - Medical News Today, accessed July 30, 2025, https://www.medicalnewstoday.com/articles/drugs-citalopram-tablet-side-effects
23. Citalopram: Uses, Dosage, Side Effects - Drugs.com, accessed July 30, 2025, https://www.drugs.com/citalopram.html
24. medlineplus.gov, accessed July 30, 2025, https://medlineplus.gov/druginfo/meds/a699001.html
25. The 6 Medications and Substances That May Cause Citalopram Interactions - GoodRx, accessed July 30, 2025, https://www.goodrx.com/citalopram/interactions
26. Celexa Interactions: Alcohol, Medications, and Others - Healthline, accessed July 30, 2025, https://www.healthline.com/health/drugs/celexa-interactions
27. Citalopram: Side Effects, Dosage, Uses, and More - Healthline, accessed July 30, 2025, https://www.healthline.com/health/drugs/citalopram-oral-tablet